Kanvas Biosciences Raises $48M in Series A to Advance Microbiome-Based Cancer Therapies
Biotech usually talks like it’s reading from a hostage note written by a patent attorney. Then a company like Kanvas Biosciences walks into the room carrying microscopes, microbial consortia, spatial imaging, and enough ambition to make Big Pharma check its pulse twice. Princeton, New Jersey just watched Kanvas Biosciences pull in $48M in Series A funding, bringing total funding to $78M, and the round reads like a table where serious operators quietly move industries while everyone else on the internet debates productivity hacks between cold plunges and espresso selfies.
DCVC and Lions Capital LLC co-led the round, with participation from the Gates Foundation, ATHOS KG, Germin8, Ki Tua Fund, and Pangaea Ventures. That is not tourist money. That is “we spent time in the engine room before wiring the capital” money. Investors are not tossing checks at biotech fairy dust anymore. They want platforms. Infrastructure. Manufacturing. Repeatability. They want companies that can survive contact with regulators, clinical trials, and the cruel little math problem called reality. Kanvas Biosciences built exactly that.
Matthew P. Cheng, Hao Shi, and Iwijn De Vlaminck did not build another biotech deck stuffed with glowing DNA graphics that look like rejected screensavers from a Vegas casino lobby. They built a full-stack spatial biology and microbiome therapeutics company capable of screening, discovering, and manufacturing live biotherapeutic products under one roof. Different game entirely. Most companies focus on one layer of the process and hope partnerships fill the gaps later. Kanvas Biosciences decided to build the entire machine themselves.
The company’s HiPR-FISH platform sounds like something NASA would use to locate microbial life under Martian ice, and honestly, it carries that same kind of energy. The technology maps microbial communities directly inside tissue while revealing how microbes and host cells interact in real time. Translation for the non-scientists sitting in the cheap seats: Kanvas Biosciences is trying to understand not just who is inside the body, but what they are saying to each other when disease enters the room wearing polished shoes and a fake smile.
That matters because roughly 90% of solid organ cancer patients do not fully respond to immune checkpoint inhibitors. Read that one twice. Immunotherapy changed medicine, but there is still a canyon between scientific promise and patient outcome. Kanvas Biosciences is betting the microbiome is one of the missing coordinates. Their lead candidate, KAN-001, is designed to improve immunotherapy efficacy using defined microbial consortia instead of the biological roulette wheel medicine has tolerated for decades.
And this is where the story starts throwing elbows. Kanvas Biosciences is not just discovering therapies. They are manufacturing them too through a clinical-phase GMP facility in South San Francisco. Discovery without manufacturing is like designing an engine with no factory capable of building it at scale. Matthew P. Cheng, Hao Shi, Phil Burnham, Lee Swem, Steve Kujawa, and the broader Kanvas Biosciences team are building both the infrastructure and the operational muscle while the market is still trying to figure out where immuno-oncology heads next. Jason Pontin and the DCVC crew clearly saw something early here too, because this company feels less like a science project and more like infrastructure for the future of microbiome-driven cancer therapy.
